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Abstract Chemical synthesis of bioactive peptides has become a 
widespread and rapidly growing technique due to automated and 
efficient protocols for chain assembly. For most applications, the 
crude synthetic product must be purified to remove residual 
reactants, failure sequences and chemically modified peptide 
species. We propose here a method of universal applicability 
based on immobilized metal ion affinity chromatography, CNBr 
cleavage and use of reversible Met-sulfoxide protection. With 
this method we were able to purify to homogeneity in high yield 
the PbCS 242-310 polypeptide corresponding to the C-terminal 
region of Plasmodium berghei CS protein. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
During the last decade solid phase peptide synthesis, using 
either t-Boc or F-moc strategies, has been largely improved. 
Sophisticated protocols of synthesis have allowed the prepa-
ration of polypeptides of 70 or more residues [1-5]. Never-
theless, incomplete coupling and chain termination that may 
occur during any cycle of peptide assembly lead to the for-
mation of deletion and truncated sequences. Such problems 
together with the possible occurrence of side reactions ob-
served mainly during final cleavage from the resin hamper 
straightforward separation of the desired peptide from other 
impurities. The purification of long synthetic polypeptides is a 
major problem in the production of products useful for bio-
logical studies or for human and animal use where a high level 
of purity is mandatory. In particular, when sequences contain-
ing 30 or more residues are synthesized, differences in physical 
properties such as size, charge and hydrophobicity between 
the desired product and deleted, truncated or modified peptide 
impurities may be too small to allow adequate purification. In 
addition, modern powerful separation techniques, such as re-
verse phase HPLC, are often limited by low yields and small 
sample 'loadability' which is time consuming and expensive. 
Different approaches to circumvent these limitations have 
been tested. Biotinylation of a 153 residue IL-1 synthetic pro-
tein [6] and a 99 residue SIV protease synthetic protein [7] was 
performed and the biotinylated chains were isolated on avi-
din-agarose columns. Ball et al. [8] recently proposed a puri-
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fication procedure based on the addition of a reversible pro-
tecting group bearing a lipophilic, acidic or basic function to 
the last residue of the peptide chain. More specific Chromato-
graphie methods have been optimized exploiting the presence 
of particular residues in the synthesized sequences. For exam-
ple, cysteine-containing peptides have been purified by reac-
tion with immobilized mercury derivatives [9] or activated 
thiols [10]. In addition, immobilized metal ion affinity chro-
matography (IMAC) [11] has been successfully applied for the 
purification of peptides containing histidine or tryptophan [12] 
or recombinant proteins to which a histidine tail was pur-
posely added. Taking advantage of this latter approach we 
developed a purification procedure of general applicability 
based on the combination of: (1) a simple capping protocol 
and replacement of methionine residue(s), if present, with me-
thionine sulfoxide during assembly of the native sequence; (2) 
N-terminal elongation of the desired peptide with 1 methio-
nine, 2 glycine residues and a terminal stretch of 6 histidines; 
(3) after acid cleavage, purification of the peptide by immo-
bilized Ni affinity chromatography followed by cyanogen bro-
mide cleavage of the histidine tail and, if necessary, final re-
duction of methionine sulfoxide to methionine. This simple 
strategy allowed rapid purification to homogeneity of the 69 
residue polypeptide PbCS 242-310, covering the C-terminal 
region of the P. berghei CS protein [13], in high yield and 
using only inexpensive Chromatographie procedures. 
2. Materials and methods 
2.1. Reagents and solvents 
Chemicals and solvents used for the peptide synthesis were pur-
chased from Calbiochem-Novabiochem AG (Läufelfingen, Switzer-
land) and Fluka (Buchs, Switzerland). 
2.2. Peptide synthesis 
The polypeptide PbCS 242-310 covering the C-terminal region of 
P. berghei CS protein [13] was chemically synthesized using solid 
phase F-moc chemistry in an Applied Biosystems 431A Peptide Syn-
thesizer. The polypeptide was prepared on a Fmoc-Ser(t-butyl)-p-al-
koxybenzylalkohol resin (Wang resin) with a degree of substitution of 
0.43 mmol/g at the 0.1 mmol scale. The synthesis was performed using 
a five-fold excess of F-moc amino acid derivatives, DCCI and HOBt 
as activating agents, a 60 min coupling time for the first 34 amino 
acids and a double coupling for the following residues. Capping with 
acetic anhydride was performed at the end of each cycle. Side chain 
protecting groups included: t-butylthio group for Cys; pentamethyl-
chroman-sulfonyl group for Arg; triphenylmethyl group for Asn, Gin 
and His; t-butoxycarbonyl group for Lys and Trp; t-butyl group for 
Asp, Glu, Ser, Thr and Tyr. Met 306 was inserted as Fmoc-Met-
sulfoxide. The peptide was then elongated N-terminally with the se-
quence His-His-His-His-His-His-Gly-Gly-Met using the same condi-
tions described above but capping was omitted after coupling of the 
second Gly. Crude peptide was obtained by treating the peptide resin 
with 2.5% H2O, 5% triethylsilan in TFA for 2 h at room temperature. 
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Synthetic peptide was desalted and partially purified from low MW 
fragments by size exclusion liquid chromatography (Sephadex G50 
column 70x2.5 cm using 50% acetic acid/T^O as mobile phase). 
2.3. IMAC and CNBr cleavage 
A Ni-column was prepared with 25 ml Ni-NTA agarose resin (Qia-
gen Inc., Chatsworth, USA) and equilibrated with buffer A (8 M urea, 
0.1 M Na 2HP0 4 , 0.01 M Tris, pH adjusted to 8.0 with H3P04) . Size 
exclusion purified His tag PbCS 242-310 polypeptide was dissolved in 
buffer A and loaded on the column with a flow rate of 15 ml/h. The 
column was washed with buffer A (flow rate 15 ml/h) and buffer B (8 
M urea, 0.1 M Na 2HP0 4 , 0.01 M Tris, pH adjusted to 6.3 with 
H3PO4) containing 50 mM imidazole at a flow rate of 30 ml/h. The 
His tag PbCS 242-310 polypeptide was then eluted (flow rate 30 ml/h) 
with buffer B containing 250 mM imidazole. The eluted material was 
desalted by a Sephadex G25 column (50x2.5 cm using 50% acetic 
Fig. 1. Analytical HPLC profiles and mass spectra of A: crude, and B: purified peptide. The HPLC chromatograms were obtained injecting 
100 μg of each sample and monitoring at 280 nm with an a.u.f.s. of 0.2. 
M.A. Roggero et al.lFEBS Letters 408 (1997) 285-288 287 
acid/H20 as mobile phase), lyophilized and treated for 8 h at RT at a 
concentration of 20 mg/ml in 70% TFA using a 100-fold molar excess 
of CNBr. The digested material was lyophilized, solubilized in buffer 
A and loaded again on the Ni-NTA agarose column. The flow 
through of the column was desalted by a Sephadex G25 column 
(50x2.5 cm using 50% acetic acid/H20 as mobile phase) and lyophi-
lized. 
2.4. Cys deprotection and Met-sulfoxide reduction 
The CNBr treated and IMAC purified material was treated with 
10% ß-mercaptoethanol [14] in buffer A and further purified by gel 
filtration (Sephadex G25 column 250x4.4 mm). 
2.5. Peptide analysis 
The purity of peptide was analysed by RP-HPLC using a C4 W-
Porex 250X4.6 mm column and a 10-90% CH3CN gradient in 0.1% 
TFA/H20 in 60 min with a flow rate of 1.0 ml/min. The amino acid 
composition was determined according to Knecht and Chang [15]. 
2.6. Mass spectrometry 
Mass spectrometry analysis was performed using a time of flight 
mass spectrometer LDI 1700 Mass Monitor (Linear Scientific Inc., 
Reno, NV, USA). Five μΐ of 1 mg/ml of polypeptide were mixed 
with 5 μΐ of trans-3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic 
acid) 20 mg/ml in acetonitrile (Linear Scientific Inc., Reno, NV, 
USA) and 1.0 μΐ of this solution was placed on the mass spectrometer 
probe tip and dried with a gently vacuum. The sample was irradiated 
with 3 ns laser pulses (wavelength 337 nm) from a N2 laser. Time of 
flight was measured with a digital oscilloscope (series 9304; Le Croy 
Research Systems, Corp., Spring Valley, NY, USA) which was con-
verted into mass spectrum using the Peptide MALDI-TOF MS Cal-
ibration Standard (Linear Scientific Inc., Reno, NV, USA). 
3. Results 
The 69 residue polypeptide PbCS 242-310 corresponds to 
the C-terminal region of P. berghei CS protein [13]. Synthesis 
of His tag PbCS 242-310 was performed using an automated 
protocol in which a capping step was included after each 
coupling as described in Section 2. More than 150 mg of crude 
polypeptide were obtained by treating 600 mg of the corre-
sponding peptide resin. Mass spectral analysis indicated the 
presence of the species of interest (9301.5, expected 
MW = 9305) together with other low MW components (Fig. 
1A). The peptide mixture was partially purified by size exclu-
sion liquid Chromatograph. Ninety mg of size exclusion puri-
fied His tag PbCS 242-310 polypeptide were purified by 
IMAC on a 25 ml Ni-column (Fig. 2). The purified material 
was CNBr digested and loaded again on the Ni-NTA agarose 
column to eliminate the histidine tail and undigested peptide. 
The purified PbCS 242-310 polypeptide was then treated with 
ß-mercaptoethanol to deprotect the blocked cysteines and to 
reduce Met-sulfoxide 306 to methionine. After gel filtration, 
19 mg of pure polypeptide were finally recovered, correspond-
ing to approximately 20% of the initial crude material. In Fig. 
1, the analytical Chromatographie profiles and mass spectra of 
crude (A) and final purified peptide (B) are compared. The 
difference of retention times between the two runs is due to 
the absence of the highly charged His tail in the purified 
material. Purified PbCS 242-310 was found to be approxi-
mately 95% pure based on the integration of peak areas 
when analysed at 214 nm. The amino acid composition of 
the CS polypeptide was consistent with that expected for 
this peptide (data not shown). Mass spectral analysis gave a 
MW of 7886.7 instead of the expected 7869 MW. This differ-
ence is probably due to the presence of a sodium ion. 
4. Discussion 
The purification methods described so far for long peptides 
are not completely satisfactory since they are still time con-
suming and/or leave covalently derivatized peptides in the 
final purified products which may interfere or alter their bio-
logical and physico-chemical properties and their eventual uti-
lization in animal and human experiments. In contrast, the 
procedure described here appears to meet the requirements 
of universality, high yield of recovery and easiness of the 
purification steps involved. This was achieved by insertion 
of a methionine residue before the affinity tag (stretch of 6 
histidine residues or other purification facilitating compounds) 
followed, after appropriate purification steps, by elimination 
of the histidine tail by CNBr digestion, an inexpensive and 
very efficient process. The problem of the presence of Met 
residues in the desired sequence, as in our case, is easily cir-
cumvented using Met-sulfoxide residues which are resistant to 
CNBr treatment and quantitatively reducible with ß-mercap-
toethanol [14]. We have successfully applied this protocol to 
the purification of the polypeptide PbCS 242-310, a 69 residue 
chain corresponding to the C-terminal region of P. berghei CS 
protein [13]. Although many peptide impurities were present 
in the crude material after cleavage from the resin as shown 
by mass spectral analysis reported in Fig. 1, we were able to 
purify the target peptide to homogeneity in high yield and in 
relatively short time. The complete protocol of purification 
yielded 19 mg of purified PbCS 242-310, corresponding to 
approximately 20% of the crude material. 
In conclusion, we have demonstrated here that purification 
using an His affinity tag, the specificity of the CNBr cleavage, 
and use of a reversible Met-sulfoxide protection in native 
sequence assembly can represent a novel general protocol 
for the efficient purification of solid phase synthesized poly-
peptides. 
Fig. 2. Chromatographie profile of IMAC purification. 
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